Back to top
more

Inogen (INGN)

(Delayed Data from NSDQ)

$8.69 USD

8.69
111,109

-0.04 (-0.46%)

Updated Nov 1, 2024 03:59 PM ET

After-Market: $8.69 0.00 (0.00%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Add IDEXX (IDXX) to Your Portfolio Now

by Zacks Equity Research

Investors are optimistic about IDEXX (IDXX) on strong growth in CAG business and bullish 2021 outlook.

Medtronic (MDT) Progresses in SCS With FDA Nod for Vanta

by Zacks Equity Research

Vanta utilizes Medtronic's (MDT) proprietary AdaptiveStim technology for personalized pain relief.

Teleflex (TFX) Procedure Volume Recovers as Pandemic Subsides

by Zacks Equity Research

The UroLift System remains a major contributor to Teleflex (TFX) revenues.

Edwards Lifesciences (EW) at a 52-Week High: What's Driving It?

by Zacks Equity Research

Investors are optimistic about Edwards Lifesciences (EW) on its promising Surgical Structural Heart business and bullish 2021 guidance.

Henry Schein (HSIC) Enhances Dental Practices With New Deal

by Zacks Equity Research

Henry Schein's (HSIC) acquisition of majority stake in eAssist will enable it to offer best quality solutions to help dental practices operate efficiently and profitably.

CVS Health (CVS) Deploys Time-Delay Safes in Georgia Pharmacies

by Zacks Equity Research

CVS Health's (CVS) time-delay safes are anticipated to help reduce robbery incidents.

Thermo Fisher (TMO) End Markets Rebound as COVID-19 Cases Drop

by Zacks Equity Research

In academic and government end markets, Thermo Fisher (TMO) grows on robust customer activity globally.

Medtronic (MDT) Progresses in Neuromodulation on New FDA Nod

by Zacks Equity Research

Medtronic's (MDT) SenSight claims to deliver patient-specific DBS therapy for the treatment of symptoms associated with Parkinson's, dystonia and essential tremor and medically refractory epilepsy.

Here's Why You Should Retain CVS Health (CVS) in Your Portfolio

by Zacks Equity Research

Investors are optimistic about CVS Health (CVS) on solid first-quarter performance and growth in digital health services.

STERIS (STE) Expands Product Suite With New Acquisition

by Zacks Equity Research

STERIS' (STE) acquisition of Cantel Medical will complement and broaden the former's product and service offerings, global reach and customers.

Inogen (INGN) Down 11.5% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Here's Why You Should Add Inogen (INGN) to Your Portfolio

by Zacks Equity Research

Investors continue to be optimistic about Inogen (INGN) on its direct-to-customer business model and a strong product portfolio.

Inogen (INGN) Q1 Loss Narrower Than Expected, Revenues Beat

by Zacks Equity Research

Inogen (INGN) gains traction from revenue growth within its Rental segment in Q1.

Inogen (INGN) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inogen (INGN) delivered earnings and revenue surprises of 89.29% and 8.44%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Urmimala Biswas headshot

4 Medical Products Stocks Set to Beat This Earnings Season

by Urmimala Biswas

Rebound in base sales make us optimistic about OMI, INGN, XRAY and CNTG's results this time around.

Inogen's (INGN) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Inogen, Inc. (INGN).

Owens & Minor (OMI) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

Owens & Minor (OMI) witnesses rebound in demand for elective procedures through the months of Q1.

InMode (INMD) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research

InMode's (INMD) Morpheus8 Platform and Morpheus8 Body that use RF fractional technology are expected to have continued to contribute to the company's Q1 top line.

Why Is Inogen (INGN) Down 9.4% Since Last Earnings Report?

by Zacks Equity Research

Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Inogen (INGN) Q4 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Inogen's (INGN) fourth-quarter results benefit from higher rental revenues and strength in business-to-business revenues.

Inogen (INGN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Inogen (INGN) delivered earnings and revenue surprises of 17.86% and 6.92%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Inogen (INGN) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Inogen (INGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Inogen (INGN) Up 35.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Inogen (INGN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Inogen (INGN) Stock Loses 9.2% After Delivering Loss in Q3

by Zacks Equity Research

Inogen (INGN) saw revenue decline within its Sales segment in Q3

Inogen (INGN) Reports Q3 Loss, Misses Revenue Estimates

by Zacks Equity Research

Inogen (INGN) delivered earnings and revenue surprises of -300.00% and -0.82%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?